Elevated blood glucose and glycemic fluctuations in diabetic individuals trigger inflammation, leading to microvascular alterations characteristic of DR
When GLP 1 is not an option: alternatives that still move the needle For patients with contraindications, we design personalized plans using non GLP peptides, metabolic support strategies, or regenerative approaches that still move the needle safely
Ozempic usually brings down A1C by 1.5-2 points , while Mounjaro can increase that reduction to 2-2.5 points in many cases, partly because it works on two different receptors
There are also concerns, based on an animal and biomarker data, of a possible link to certain types of cancer
Others track it in a phone note
Diabetes Care 42(6):991993